These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 9258358)

  • 1. Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits.
    MacPherson LJ; Bayburt EK; Capparelli MP; Carroll BJ; Goldstein R; Justice MR; Zhu L; Hu S; Melton RA; Fryer L; Goldberg RL; Doughty JR; Spirito S; Blancuzzi V; Wilson D; O'Byrne EM; Ganu V; Parker DT
    J Med Chem; 1997 Aug; 40(16):2525-32. PubMed ID: 9258358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of stromelysin-1 (MMP-3) by P1'-biphenylylethyl carboxyalkyl dipeptides.
    Esser CK; Bugianesi RL; Caldwell CG; Chapman KT; Durette PL; Girotra NN; Kopka IE; Lanza TJ; Levorse DA; MacCoss M; Owens KA; Ponpipom MM; Simeone JP; Harrison RK; Niedzwiecki L; Becker JW; Marcy AI; Axel MG; Christen AJ; McDonnell J; Moore VL; Olszewski JM; Saphos C; Visco DM; Hagmann WK
    J Med Chem; 1997 Mar; 40(6):1026-40. PubMed ID: 9083493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NMR solution structure of the catalytic fragment of human fibroblast collagenase complexed with a sulfonamide derivative of a hydroxamic acid compound.
    Moy FJ; Chanda PK; Chen JM; Cosmi S; Edris W; Skotnicki JS; Wilhelm J; Powers R
    Biochemistry; 1999 Jun; 38(22):7085-96. PubMed ID: 10353819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases.
    Pikul S; McDow Dunham KL; Almstead NG; De B; Natchus MG; Anastasio MV; McPhail SJ; Snider CE; Taiwo YO; Chen L; Dunaway CM; Gu F; Mieling GE
    J Med Chem; 1999 Jan; 42(1):87-94. PubMed ID: 9888835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of potent, selective, and orally active carboxylic acid based inhibitors of matrix metalloproteinase-13.
    Monovich LG; Tommasi RA; Fujimoto RA; Blancuzzi V; Clark K; Cornell WD; Doti R; Doughty J; Fang J; Farley D; Fitt J; Ganu V; Goldberg R; Goldstein R; Lavoie S; Kulathila R; Macchia W; Parker DT; Melton R; O'Byrne E; Pastor G; Pellas T; Quadros E; Reel N; Roland DM; Sakane Y; Singh H; Skiles J; Somers J; Toscano K; Wigg A; Zhou S; Zhu L; Shieh WC; Xue S; McQuire LW
    J Med Chem; 2009 Jun; 52(11):3523-38. PubMed ID: 19422229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ro 32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo.
    Lewis EJ; Bishop J; Bottomley KM; Bradshaw D; Brewster M; Broadhurst MJ; Brown PA; Budd JM; Elliott L; Greenham AK; Johnson WH; Nixon JS; Rose F; Sutton B; Wilson K
    Br J Pharmacol; 1997 Jun; 121(3):540-6. PubMed ID: 9179398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and preliminary biological evaluation of new radioiodinated MMP inhibitors for imaging MMP activity in vivo.
    Kopka K; Breyholz HJ; Wagner S; Law MP; Riemann B; Schröer S; Trub M; Guilbert B; Levkau B; Schober O; Schäfers M
    Nucl Med Biol; 2004 Feb; 31(2):257-67. PubMed ID: 15013492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the pharmacology of hydroxamate- and carboxylate-based matrix metalloproteinase inhibitors (MMPIs) for the treatment of osteoarthritis.
    Janusz MJ; Hookfin EB; Brown KK; Hsieh LC; Heitmeyer SA; Taiwo YO; Natchus MG; Pikul S; Almstead NG; De B; Peng SX; Baker TR; Patel V
    Inflamm Res; 2006 Feb; 55(2):60-5. PubMed ID: 16612565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-resolution solution structure of the catalytic fragment of human collagenase-3 (MMP-13) complexed with a hydroxamic acid inhibitor.
    Moy FJ; Chanda PK; Chen JM; Cosmi S; Edris W; Levin JI; Powers R
    J Mol Biol; 2000 Sep; 302(3):671-89. PubMed ID: 10986126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers.
    Fray MJ; Dickinson RP; Huggins JP; Occleston NL
    J Med Chem; 2003 Jul; 46(16):3514-25. PubMed ID: 12877590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel series of highly selective inhibitors of MMP-3.
    Whitlock GA; Dack KN; Dickinson RP; Lewis ML
    Bioorg Med Chem Lett; 2007 Dec; 17(24):6750-3. PubMed ID: 18029177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 18F-radiolabeled analogue of CGS 27023A as a potential agent for assessment of matrix-metalloproteinase activity in vivo.
    Breyholz HJ; Wagner S; Levkau B; Schober O; Schäfers M; Kopka K
    Q J Nucl Med Mol Imaging; 2007 Mar; 51(1):24-32. PubMed ID: 17372570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matrix metalloproteinase inhibitor CGS 27023A protects COMP and proteoglycan in the bovine articular cartilage but not the release of their fragments from cartilage after prolonged stimulation in vitro with IL-1 alpha.
    Ganu V; Melton R; Wang W; Roberts D
    Ann N Y Acad Sci; 1999 Jun; 878():607-11. PubMed ID: 10415786
    [No Abstract]   [Full Text] [Related]  

  • 14. Oral administration of a matrix metalloproteinase inhibitor, CGS 27023A, protects the cartilage proteoglycan matrix in a partial meniscectomy model of osteoarthritis in rabbits.
    O'Byrne EM; Parker DT; Roberts ED; Goldberg RL; MacPherson LJ; Blancuzzi V; Wilson D; Singh HN; Ludewig R; Ganu VS
    Inflamm Res; 1995 Aug; 44 Suppl 2():S117-8. PubMed ID: 8548356
    [No Abstract]   [Full Text] [Related]  

  • 15. The effect of CGS 27023A on the level of 3B3 (-) epitope in a rabbit meniscectomy model.
    Doughty JR; O'Byrne E; Spirito S; Blancuzzi V; Singh HN; Goldberg RL
    Inflamm Res; 1997 Aug; 46 Suppl 2():S139-40. PubMed ID: 9297550
    [No Abstract]   [Full Text] [Related]  

  • 16. Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.
    Schnute ME; O'Brien PM; Nahra J; Morris M; Howard Roark W; Hanau CE; Ruminski PG; Scholten JA; Fletcher TR; Hamper BC; Carroll JN; Patt WC; Shieh HS; Collins B; Pavlovsky AG; Palmquist KE; Aston KW; Hitchcock J; Rogers MD; McDonald J; Johnson AR; Munie GE; Wittwer AJ; Man CF; Settle SL; Nemirovskiy O; Vickery LE; Agawal A; Dyer RD; Sunyer T
    Bioorg Med Chem Lett; 2010 Jan; 20(2):576-80. PubMed ID: 20005097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crystal structure of the stromelysin catalytic domain at 2.0 A resolution: inhibitor-induced conformational changes.
    Chen L; Rydel TJ; Gu F; Dunaway CM; Pikul S; Dunham KM; Barnett BL
    J Mol Biol; 1999 Oct; 293(3):545-57. PubMed ID: 10543949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new 18F-labelled derivative of the MMP inhibitor CGS 27023A for PET: radiosynthesis and initial small-animal PET studies.
    Wagner S; Breyholz HJ; Höltke C; Faust A; Schober O; Schäfers M; Kopka K
    Appl Radiat Isot; 2009 Apr; 67(4):606-10. PubMed ID: 19167232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis of a series of stromelysin-selective thiadiazole urea matrix metalloproteinase inhibitors.
    Jacobsen EJ; Mitchell MA; Hendges SK; Belonga KL; Skaletzky LL; Stelzer LS; Lindberg TJ; Fritzen EL; Schostarez HJ; O'Sullivan TJ; Maggiora LL; Stuchly CW; Laborde AL; Kubicek MF; Poorman RA; Beck JM; Miller HR; Petzold GL; Scott PS; Truesdell SE; Wallace TL; Wilks JW; Fisher C; Goodman LV; Kaytes PS
    J Med Chem; 1999 May; 42(9):1525-36. PubMed ID: 10229623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amber force field implementation, molecular modelling study, synthesis and MMP-1/MMP-2 inhibition profile of (R)- and (S)-N-hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3-methylbutanamides.
    Tuccinardi T; Martinelli A; Nuti E; Carelli P; Balzano F; Uccello-Barretta G; Murphy G; Rossello A
    Bioorg Med Chem; 2006 Jun; 14(12):4260-76. PubMed ID: 16483784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.